Sun, Feb 1, 2015, 8:01 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

  • jbc7719 jbc7719 Sep 8, 2011 6:14 AM Flag

    Strange that Perifosine not pricing in..

    I could understand if Perifosine was a phase I candidate, but to trade under $2 at this point is Twillight Zone strange. Based off better than average probablity of acutally making it to market PPS should be rising steadily as AEZS moves closer to an tail end event, yet it really isn't, not when stacked against the PPS of KERX.

    We continue to witness the strange journey of AEZS.

    What comes first for shareholders? Material news or PPS plunge due to global economic meltdown?

    In hind sight it would seem like a foolish gamble to let KERX own the U.S market for perifosine and I think it may be one of the main factors depressing price here.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I have been trading both AEZS and KERX for over a year now. The reason KERX is trading at a higher price than AEZS because more institutions were trading KERX. The reason more institution were trading KERX is because it is an American company. More marketing research had done on American biotech companies than Canadian biotech companies. So, it is a matter of exposure to the marketers. If Perifosine is approved, AEZS will be equally attractive as KERX. Obama's Medicaid and Medicare change has negatively affected DNDN's sales of PROVENGE. It will also negatively affect KERX's sale of Perifosine in the US market if it gets approved by the FDA. So my point is the stock price of AEZS will be higher than KERX if Perifosine is approved FDA and Obama is still the president.

    • I tend to agree... I'm not sure why we don't mirror Kerx rise in stock price or at least be closer to it...

      • 1 Reply to tiger50118
      • I can't remember another bio with such a strong pipeline, early and late stage trade like this. KERX trading higher reflects the potential of the U.S market, which is huge. I wish AEZS had found a way to keep the U.S market for themselves. Although it probably would have meant pain for shareholders, i.e dilution if perifosine does make it, holding the U.S market would have been worth it.

        Best of luck guys. Hopefully the ball leaves the park eventually....

 
AEZS
0.53-0.01(-1.85%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Breitburn Energy Partners L.P.
NASDAQFri, Jan 30, 2015 4:00 PM EST
ImmunoGen, Inc.
NASDAQFri, Jan 30, 2015 4:00 PM EST